Journal for ImmunoTherapy of Cancer-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2180016, encodeId=3f3221800163f, content=Research Reporting Guideline checklist在哪里啊，没有找的呢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a6a8156000, createdName=ms1000000367938648, createdTime=Mon Jan 08 16:31:56 CST 2024, time=2024-01-08, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2142895, encodeId=efe42142895b8, content=为什么一直保持10分以上，还是中科院二区，还不如BMC medicine吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18525506506, createdName=ms4000001058776765, createdTime=Thu Jun 15 09:34:20 CST 2023, time=2023-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=911223, encodeId=111b91122357, content=现在状态是awaiting decision，是凉的意思吗？还是说内审决定送不送外审都会有这个状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48aa5286894, createdName=148555c3m25(暂无昵称), createdTime=Sun Dec 27 11:54:15 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997775, encodeId=d6f099e775b4, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤免疫;纳米 经验分享：03.17 投稿，很快进入审稿阶段； 04.06 大修，期限2个月； 05.05 大修返回，很快进入审稿阶段； 06.02 接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e91c38967, createdName=yelinghao215, createdTime=Fri Jul 09 08:38:11 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186239, encodeId=f23a218623976, content=EPA: Not Assigned。Awaiting Editorial Production Assistant Processing 刚提交显示这个正常吗？作者都没有收到邮件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=059b5442634, createdName=NWH, createdTime=Tue Feb 06 17:02:40 CST 2024, time=2024-02-06, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2119814, encodeId=4c2a211981487, content=偏重的研究方向：乳腺癌 经验分享：已经在Reviewer selection 和Reviewer Assignment之间反复横跳1个月了，煎熬。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Wed Mar 15 22:55:25 CST 2023, time=2023-03-15, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1223473, encodeId=4d9112234e326, content=审稿速度:1.0 经验分享：5月1 投稿 5月17 awaiting reviewer scores 5月26 告知主编将发decision letter 5月27 早上7:30，小修香港疫情好转，现在加班加点改稿子中，要补的一个实验猜中，提前在等待中做完了，希望好运🍀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=794e8145109, createdName=ms2000001308610491, createdTime=Mon May 30 23:16:38 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119822, encodeId=05ea211982212, content=这个杂志综述好投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ec38179859, createdName=ms5000001365142656, createdTime=Wed Mar 15 23:32:00 CST 2023, time=2023-03-15, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1057918, encodeId=6cda105e9181e, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗;病原生物 经验分享：再被cns子刊一顿拒稿之后，终于在这接收了。从投稿到接收，一直都非常迅速，感人主编很给力。 4.22提交 5.4一审大修遇到两个发nature大佬，提了一大堆意见，其中1号一直很很肯定我们的研究 6.23修回 7.14二审大修 2号审稿人同意接收，可惜1号换人了，提了几个和文章无关很无理的问题 9.15修回 9.24三审小修几个单词错误，迅速修回去 9.27修回 10.1 接收 希望大家都好运，搞个科研不容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/07/ccdcbbe305c3370f7fc7637823aaeac0.jpg, createdBy=07fb2397125, createdName=浅沫, createdTime=Tue Oct 05 16:42:40 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065742, encodeId=9dda1065e429f, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2600.0 偏重的研究方向：肿瘤免疫 经验分享：投稿两周，转态由 Awaiting reviewer selection 到Awaiting reviewer assignment 一周，10天左右变成Awaiting Recommendation，这是送外审还是没送哇，，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0985683001, createdName=ms3000001376117297, createdTime=Mon Nov 01 11:12:57 CST 2021, time=2021-11-01, status=1, ipAttribution=)]

2024-01-08 ms1000000367938648 来自四川省

Research Reporting Guideline checklist在哪里啊，没有找的呢

13 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2180016, encodeId=3f3221800163f, content=Research Reporting Guideline checklist在哪里啊，没有找的呢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a6a8156000, createdName=ms1000000367938648, createdTime=Mon Jan 08 16:31:56 CST 2024, time=2024-01-08, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2142895, encodeId=efe42142895b8, content=为什么一直保持10分以上，还是中科院二区，还不如BMC medicine吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18525506506, createdName=ms4000001058776765, createdTime=Thu Jun 15 09:34:20 CST 2023, time=2023-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=911223, encodeId=111b91122357, content=现在状态是awaiting decision，是凉的意思吗？还是说内审决定送不送外审都会有这个状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48aa5286894, createdName=148555c3m25(暂无昵称), createdTime=Sun Dec 27 11:54:15 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997775, encodeId=d6f099e775b4, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤免疫;纳米 经验分享：03.17 投稿，很快进入审稿阶段； 04.06 大修，期限2个月； 05.05 大修返回，很快进入审稿阶段； 06.02 接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e91c38967, createdName=yelinghao215, createdTime=Fri Jul 09 08:38:11 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186239, encodeId=f23a218623976, content=EPA: Not Assigned。Awaiting Editorial Production Assistant Processing 刚提交显示这个正常吗？作者都没有收到邮件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=059b5442634, createdName=NWH, createdTime=Tue Feb 06 17:02:40 CST 2024, time=2024-02-06, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2119814, encodeId=4c2a211981487, content=偏重的研究方向：乳腺癌 经验分享：已经在Reviewer selection 和Reviewer Assignment之间反复横跳1个月了，煎熬。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Wed Mar 15 22:55:25 CST 2023, time=2023-03-15, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1223473, encodeId=4d9112234e326, content=审稿速度:1.0 经验分享：5月1 投稿 5月17 awaiting reviewer scores 5月26 告知主编将发decision letter 5月27 早上7:30，小修香港疫情好转，现在加班加点改稿子中，要补的一个实验猜中，提前在等待中做完了，希望好运🍀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=794e8145109, createdName=ms2000001308610491, createdTime=Mon May 30 23:16:38 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119822, encodeId=05ea211982212, content=这个杂志综述好投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ec38179859, createdName=ms5000001365142656, createdTime=Wed Mar 15 23:32:00 CST 2023, time=2023-03-15, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1057918, encodeId=6cda105e9181e, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗;病原生物 经验分享：再被cns子刊一顿拒稿之后，终于在这接收了。从投稿到接收，一直都非常迅速，感人主编很给力。 4.22提交 5.4一审大修遇到两个发nature大佬，提了一大堆意见，其中1号一直很很肯定我们的研究 6.23修回 7.14二审大修 2号审稿人同意接收，可惜1号换人了，提了几个和文章无关很无理的问题 9.15修回 9.24三审小修几个单词错误，迅速修回去 9.27修回 10.1 接收 希望大家都好运，搞个科研不容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/07/ccdcbbe305c3370f7fc7637823aaeac0.jpg, createdBy=07fb2397125, createdName=浅沫, createdTime=Tue Oct 05 16:42:40 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065742, encodeId=9dda1065e429f, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2600.0 偏重的研究方向：肿瘤免疫 经验分享：投稿两周，转态由 Awaiting reviewer selection 到Awaiting reviewer assignment 一周，10天左右变成Awaiting Recommendation，这是送外审还是没送哇，，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0985683001, createdName=ms3000001376117297, createdTime=Mon Nov 01 11:12:57 CST 2021, time=2021-11-01, status=1, ipAttribution=)]

2023-06-15 ms4000001058776765 来自北京

为什么一直保持10分以上，还是中科院二区，还不如BMC medicine吗？

35 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2180016, encodeId=3f3221800163f, content=Research Reporting Guideline checklist在哪里啊，没有找的呢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a6a8156000, createdName=ms1000000367938648, createdTime=Mon Jan 08 16:31:56 CST 2024, time=2024-01-08, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2142895, encodeId=efe42142895b8, content=为什么一直保持10分以上，还是中科院二区，还不如BMC medicine吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18525506506, createdName=ms4000001058776765, createdTime=Thu Jun 15 09:34:20 CST 2023, time=2023-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=911223, encodeId=111b91122357, content=现在状态是awaiting decision，是凉的意思吗？还是说内审决定送不送外审都会有这个状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48aa5286894, createdName=148555c3m25(暂无昵称), createdTime=Sun Dec 27 11:54:15 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997775, encodeId=d6f099e775b4, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤免疫;纳米 经验分享：03.17 投稿，很快进入审稿阶段； 04.06 大修，期限2个月； 05.05 大修返回，很快进入审稿阶段； 06.02 接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e91c38967, createdName=yelinghao215, createdTime=Fri Jul 09 08:38:11 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186239, encodeId=f23a218623976, content=EPA: Not Assigned。Awaiting Editorial Production Assistant Processing 刚提交显示这个正常吗？作者都没有收到邮件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=059b5442634, createdName=NWH, createdTime=Tue Feb 06 17:02:40 CST 2024, time=2024-02-06, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2119814, encodeId=4c2a211981487, content=偏重的研究方向：乳腺癌 经验分享：已经在Reviewer selection 和Reviewer Assignment之间反复横跳1个月了，煎熬。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Wed Mar 15 22:55:25 CST 2023, time=2023-03-15, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1223473, encodeId=4d9112234e326, content=审稿速度:1.0 经验分享：5月1 投稿 5月17 awaiting reviewer scores 5月26 告知主编将发decision letter 5月27 早上7:30，小修香港疫情好转，现在加班加点改稿子中，要补的一个实验猜中，提前在等待中做完了，希望好运🍀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=794e8145109, createdName=ms2000001308610491, createdTime=Mon May 30 23:16:38 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119822, encodeId=05ea211982212, content=这个杂志综述好投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ec38179859, createdName=ms5000001365142656, createdTime=Wed Mar 15 23:32:00 CST 2023, time=2023-03-15, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1057918, encodeId=6cda105e9181e, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗;病原生物 经验分享：再被cns子刊一顿拒稿之后，终于在这接收了。从投稿到接收，一直都非常迅速，感人主编很给力。 4.22提交 5.4一审大修遇到两个发nature大佬，提了一大堆意见，其中1号一直很很肯定我们的研究 6.23修回 7.14二审大修 2号审稿人同意接收，可惜1号换人了，提了几个和文章无关很无理的问题 9.15修回 9.24三审小修几个单词错误，迅速修回去 9.27修回 10.1 接收 希望大家都好运，搞个科研不容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/07/ccdcbbe305c3370f7fc7637823aaeac0.jpg, createdBy=07fb2397125, createdName=浅沫, createdTime=Tue Oct 05 16:42:40 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065742, encodeId=9dda1065e429f, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2600.0 偏重的研究方向：肿瘤免疫 经验分享：投稿两周，转态由 Awaiting reviewer selection 到Awaiting reviewer assignment 一周，10天左右变成Awaiting Recommendation，这是送外审还是没送哇，，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0985683001, createdName=ms3000001376117297, createdTime=Mon Nov 01 11:12:57 CST 2021, time=2021-11-01, status=1, ipAttribution=)]

2020-12-27 148555c3m25(暂无昵称)

现在状态是awaiting decision，是凉的意思吗？还是说内审决定送不送外审都会有这个状态

151 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2180016, encodeId=3f3221800163f, content=Research Reporting Guideline checklist在哪里啊，没有找的呢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a6a8156000, createdName=ms1000000367938648, createdTime=Mon Jan 08 16:31:56 CST 2024, time=2024-01-08, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2142895, encodeId=efe42142895b8, content=为什么一直保持10分以上，还是中科院二区，还不如BMC medicine吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18525506506, createdName=ms4000001058776765, createdTime=Thu Jun 15 09:34:20 CST 2023, time=2023-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=911223, encodeId=111b91122357, content=现在状态是awaiting decision，是凉的意思吗？还是说内审决定送不送外审都会有这个状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48aa5286894, createdName=148555c3m25(暂无昵称), createdTime=Sun Dec 27 11:54:15 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997775, encodeId=d6f099e775b4, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤免疫;纳米 经验分享：03.17 投稿，很快进入审稿阶段； 04.06 大修，期限2个月； 05.05 大修返回，很快进入审稿阶段； 06.02 接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e91c38967, createdName=yelinghao215, createdTime=Fri Jul 09 08:38:11 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186239, encodeId=f23a218623976, content=EPA: Not Assigned。Awaiting Editorial Production Assistant Processing 刚提交显示这个正常吗？作者都没有收到邮件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=059b5442634, createdName=NWH, createdTime=Tue Feb 06 17:02:40 CST 2024, time=2024-02-06, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2119814, encodeId=4c2a211981487, content=偏重的研究方向：乳腺癌 经验分享：已经在Reviewer selection 和Reviewer Assignment之间反复横跳1个月了，煎熬。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Wed Mar 15 22:55:25 CST 2023, time=2023-03-15, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1223473, encodeId=4d9112234e326, content=审稿速度:1.0 经验分享：5月1 投稿 5月17 awaiting reviewer scores 5月26 告知主编将发decision letter 5月27 早上7:30，小修香港疫情好转，现在加班加点改稿子中，要补的一个实验猜中，提前在等待中做完了，希望好运🍀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=794e8145109, createdName=ms2000001308610491, createdTime=Mon May 30 23:16:38 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119822, encodeId=05ea211982212, content=这个杂志综述好投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ec38179859, createdName=ms5000001365142656, createdTime=Wed Mar 15 23:32:00 CST 2023, time=2023-03-15, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1057918, encodeId=6cda105e9181e, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗;病原生物 经验分享：再被cns子刊一顿拒稿之后，终于在这接收了。从投稿到接收，一直都非常迅速，感人主编很给力。 4.22提交 5.4一审大修遇到两个发nature大佬，提了一大堆意见，其中1号一直很很肯定我们的研究 6.23修回 7.14二审大修 2号审稿人同意接收，可惜1号换人了，提了几个和文章无关很无理的问题 9.15修回 9.24三审小修几个单词错误，迅速修回去 9.27修回 10.1 接收 希望大家都好运，搞个科研不容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/07/ccdcbbe305c3370f7fc7637823aaeac0.jpg, createdBy=07fb2397125, createdName=浅沫, createdTime=Tue Oct 05 16:42:40 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065742, encodeId=9dda1065e429f, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2600.0 偏重的研究方向：肿瘤免疫 经验分享：投稿两周，转态由 Awaiting reviewer selection 到Awaiting reviewer assignment 一周，10天左右变成Awaiting Recommendation，这是送外审还是没送哇，，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0985683001, createdName=ms3000001376117297, createdTime=Mon Nov 01 11:12:57 CST 2021, time=2021-11-01, status=1, ipAttribution=)]

2021-07-09 yelinghao215

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：肿瘤免疫;纳米
经验分享：03.17 投稿，很快进入审稿阶段；
04.06 大修，期限2个月；
05.05 大修返回，很快进入审稿阶段；
06.02 接收。

111 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=2180016, encodeId=3f3221800163f, content=Research Reporting Guideline checklist在哪里啊，没有找的呢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a6a8156000, createdName=ms1000000367938648, createdTime=Mon Jan 08 16:31:56 CST 2024, time=2024-01-08, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2142895, encodeId=efe42142895b8, content=为什么一直保持10分以上，还是中科院二区，还不如BMC medicine吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18525506506, createdName=ms4000001058776765, createdTime=Thu Jun 15 09:34:20 CST 2023, time=2023-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=911223, encodeId=111b91122357, content=现在状态是awaiting decision，是凉的意思吗？还是说内审决定送不送外审都会有这个状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48aa5286894, createdName=148555c3m25(暂无昵称), createdTime=Sun Dec 27 11:54:15 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997775, encodeId=d6f099e775b4, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤免疫;纳米 经验分享：03.17 投稿，很快进入审稿阶段； 04.06 大修，期限2个月； 05.05 大修返回，很快进入审稿阶段； 06.02 接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e91c38967, createdName=yelinghao215, createdTime=Fri Jul 09 08:38:11 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186239, encodeId=f23a218623976, content=EPA: Not Assigned。Awaiting Editorial Production Assistant Processing 刚提交显示这个正常吗？作者都没有收到邮件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=059b5442634, createdName=NWH, createdTime=Tue Feb 06 17:02:40 CST 2024, time=2024-02-06, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2119814, encodeId=4c2a211981487, content=偏重的研究方向：乳腺癌 经验分享：已经在Reviewer selection 和Reviewer Assignment之间反复横跳1个月了，煎熬。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Wed Mar 15 22:55:25 CST 2023, time=2023-03-15, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1223473, encodeId=4d9112234e326, content=审稿速度:1.0 经验分享：5月1 投稿 5月17 awaiting reviewer scores 5月26 告知主编将发decision letter 5月27 早上7:30，小修香港疫情好转，现在加班加点改稿子中，要补的一个实验猜中，提前在等待中做完了，希望好运🍀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=794e8145109, createdName=ms2000001308610491, createdTime=Mon May 30 23:16:38 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119822, encodeId=05ea211982212, content=这个杂志综述好投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ec38179859, createdName=ms5000001365142656, createdTime=Wed Mar 15 23:32:00 CST 2023, time=2023-03-15, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1057918, encodeId=6cda105e9181e, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗;病原生物 经验分享：再被cns子刊一顿拒稿之后，终于在这接收了。从投稿到接收，一直都非常迅速，感人主编很给力。 4.22提交 5.4一审大修遇到两个发nature大佬，提了一大堆意见，其中1号一直很很肯定我们的研究 6.23修回 7.14二审大修 2号审稿人同意接收，可惜1号换人了，提了几个和文章无关很无理的问题 9.15修回 9.24三审小修几个单词错误，迅速修回去 9.27修回 10.1 接收 希望大家都好运，搞个科研不容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/07/ccdcbbe305c3370f7fc7637823aaeac0.jpg, createdBy=07fb2397125, createdName=浅沫, createdTime=Tue Oct 05 16:42:40 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065742, encodeId=9dda1065e429f, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2600.0 偏重的研究方向：肿瘤免疫 经验分享：投稿两周，转态由 Awaiting reviewer selection 到Awaiting reviewer assignment 一周，10天左右变成Awaiting Recommendation，这是送外审还是没送哇，，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0985683001, createdName=ms3000001376117297, createdTime=Mon Nov 01 11:12:57 CST 2021, time=2021-11-01, status=1, ipAttribution=)]

2024-02-06 NWH 来自湖北省

EPA: Not Assigned。Awaiting Editorial Production Assistant Processing
刚提交显示这个正常吗？作者都没有收到邮件

18 0

[GetPortalCommentsPageByObjectIdResponse(id=2180016, encodeId=3f3221800163f, content=Research Reporting Guideline checklist在哪里啊，没有找的呢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a6a8156000, createdName=ms1000000367938648, createdTime=Mon Jan 08 16:31:56 CST 2024, time=2024-01-08, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2142895, encodeId=efe42142895b8, content=为什么一直保持10分以上，还是中科院二区，还不如BMC medicine吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18525506506, createdName=ms4000001058776765, createdTime=Thu Jun 15 09:34:20 CST 2023, time=2023-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=911223, encodeId=111b91122357, content=现在状态是awaiting decision，是凉的意思吗？还是说内审决定送不送外审都会有这个状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48aa5286894, createdName=148555c3m25(暂无昵称), createdTime=Sun Dec 27 11:54:15 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997775, encodeId=d6f099e775b4, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤免疫;纳米 经验分享：03.17 投稿，很快进入审稿阶段； 04.06 大修，期限2个月； 05.05 大修返回，很快进入审稿阶段； 06.02 接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e91c38967, createdName=yelinghao215, createdTime=Fri Jul 09 08:38:11 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186239, encodeId=f23a218623976, content=EPA: Not Assigned。Awaiting Editorial Production Assistant Processing 刚提交显示这个正常吗？作者都没有收到邮件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=059b5442634, createdName=NWH, createdTime=Tue Feb 06 17:02:40 CST 2024, time=2024-02-06, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2119814, encodeId=4c2a211981487, content=偏重的研究方向：乳腺癌 经验分享：已经在Reviewer selection 和Reviewer Assignment之间反复横跳1个月了，煎熬。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Wed Mar 15 22:55:25 CST 2023, time=2023-03-15, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1223473, encodeId=4d9112234e326, content=审稿速度:1.0 经验分享：5月1 投稿 5月17 awaiting reviewer scores 5月26 告知主编将发decision letter 5月27 早上7:30，小修香港疫情好转，现在加班加点改稿子中，要补的一个实验猜中，提前在等待中做完了，希望好运🍀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=794e8145109, createdName=ms2000001308610491, createdTime=Mon May 30 23:16:38 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119822, encodeId=05ea211982212, content=这个杂志综述好投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ec38179859, createdName=ms5000001365142656, createdTime=Wed Mar 15 23:32:00 CST 2023, time=2023-03-15, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1057918, encodeId=6cda105e9181e, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗;病原生物 经验分享：再被cns子刊一顿拒稿之后，终于在这接收了。从投稿到接收，一直都非常迅速，感人主编很给力。 4.22提交 5.4一审大修遇到两个发nature大佬，提了一大堆意见，其中1号一直很很肯定我们的研究 6.23修回 7.14二审大修 2号审稿人同意接收，可惜1号换人了，提了几个和文章无关很无理的问题 9.15修回 9.24三审小修几个单词错误，迅速修回去 9.27修回 10.1 接收 希望大家都好运，搞个科研不容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/07/ccdcbbe305c3370f7fc7637823aaeac0.jpg, createdBy=07fb2397125, createdName=浅沫, createdTime=Tue Oct 05 16:42:40 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065742, encodeId=9dda1065e429f, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2600.0 偏重的研究方向：肿瘤免疫 经验分享：投稿两周，转态由 Awaiting reviewer selection 到Awaiting reviewer assignment 一周，10天左右变成Awaiting Recommendation，这是送外审还是没送哇，，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0985683001, createdName=ms3000001376117297, createdTime=Mon Nov 01 11:12:57 CST 2021, time=2021-11-01, status=1, ipAttribution=)]

2023-03-15 1321f2f792m 来自陕西省

偏重的研究方向：乳腺癌
经验分享：已经在Reviewer selection 和Reviewer Assignment之间反复横跳1个月了，煎熬。

66 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2180016, encodeId=3f3221800163f, content=Research Reporting Guideline checklist在哪里啊，没有找的呢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a6a8156000, createdName=ms1000000367938648, createdTime=Mon Jan 08 16:31:56 CST 2024, time=2024-01-08, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2142895, encodeId=efe42142895b8, content=为什么一直保持10分以上，还是中科院二区，还不如BMC medicine吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18525506506, createdName=ms4000001058776765, createdTime=Thu Jun 15 09:34:20 CST 2023, time=2023-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=911223, encodeId=111b91122357, content=现在状态是awaiting decision，是凉的意思吗？还是说内审决定送不送外审都会有这个状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48aa5286894, createdName=148555c3m25(暂无昵称), createdTime=Sun Dec 27 11:54:15 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997775, encodeId=d6f099e775b4, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤免疫;纳米 经验分享：03.17 投稿，很快进入审稿阶段； 04.06 大修，期限2个月； 05.05 大修返回，很快进入审稿阶段； 06.02 接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e91c38967, createdName=yelinghao215, createdTime=Fri Jul 09 08:38:11 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186239, encodeId=f23a218623976, content=EPA: Not Assigned。Awaiting Editorial Production Assistant Processing 刚提交显示这个正常吗？作者都没有收到邮件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=059b5442634, createdName=NWH, createdTime=Tue Feb 06 17:02:40 CST 2024, time=2024-02-06, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2119814, encodeId=4c2a211981487, content=偏重的研究方向：乳腺癌 经验分享：已经在Reviewer selection 和Reviewer Assignment之间反复横跳1个月了，煎熬。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Wed Mar 15 22:55:25 CST 2023, time=2023-03-15, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1223473, encodeId=4d9112234e326, content=审稿速度:1.0 经验分享：5月1 投稿 5月17 awaiting reviewer scores 5月26 告知主编将发decision letter 5月27 早上7:30，小修香港疫情好转，现在加班加点改稿子中，要补的一个实验猜中，提前在等待中做完了，希望好运🍀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=794e8145109, createdName=ms2000001308610491, createdTime=Mon May 30 23:16:38 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119822, encodeId=05ea211982212, content=这个杂志综述好投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ec38179859, createdName=ms5000001365142656, createdTime=Wed Mar 15 23:32:00 CST 2023, time=2023-03-15, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1057918, encodeId=6cda105e9181e, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗;病原生物 经验分享：再被cns子刊一顿拒稿之后，终于在这接收了。从投稿到接收，一直都非常迅速，感人主编很给力。 4.22提交 5.4一审大修遇到两个发nature大佬，提了一大堆意见，其中1号一直很很肯定我们的研究 6.23修回 7.14二审大修 2号审稿人同意接收，可惜1号换人了，提了几个和文章无关很无理的问题 9.15修回 9.24三审小修几个单词错误，迅速修回去 9.27修回 10.1 接收 希望大家都好运，搞个科研不容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/07/ccdcbbe305c3370f7fc7637823aaeac0.jpg, createdBy=07fb2397125, createdName=浅沫, createdTime=Tue Oct 05 16:42:40 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065742, encodeId=9dda1065e429f, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2600.0 偏重的研究方向：肿瘤免疫 经验分享：投稿两周，转态由 Awaiting reviewer selection 到Awaiting reviewer assignment 一周，10天左右变成Awaiting Recommendation，这是送外审还是没送哇，，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0985683001, createdName=ms3000001376117297, createdTime=Mon Nov 01 11:12:57 CST 2021, time=2021-11-01, status=1, ipAttribution=)]

2022-05-30 ms2000001308610491

审稿速度:1.0
经验分享：5月1 投稿 5月17 awaiting reviewer scores 5月26 告知主编将发decision letter 5月27 早上7:30，小修香港疫情好转，现在加班加点改稿子中，要补的一个实验猜中，提前在等待中做完了，希望好运🍀

99 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=2180016, encodeId=3f3221800163f, content=Research Reporting Guideline checklist在哪里啊，没有找的呢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a6a8156000, createdName=ms1000000367938648, createdTime=Mon Jan 08 16:31:56 CST 2024, time=2024-01-08, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2142895, encodeId=efe42142895b8, content=为什么一直保持10分以上，还是中科院二区，还不如BMC medicine吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18525506506, createdName=ms4000001058776765, createdTime=Thu Jun 15 09:34:20 CST 2023, time=2023-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=911223, encodeId=111b91122357, content=现在状态是awaiting decision，是凉的意思吗？还是说内审决定送不送外审都会有这个状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48aa5286894, createdName=148555c3m25(暂无昵称), createdTime=Sun Dec 27 11:54:15 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997775, encodeId=d6f099e775b4, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤免疫;纳米 经验分享：03.17 投稿，很快进入审稿阶段； 04.06 大修，期限2个月； 05.05 大修返回，很快进入审稿阶段； 06.02 接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e91c38967, createdName=yelinghao215, createdTime=Fri Jul 09 08:38:11 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186239, encodeId=f23a218623976, content=EPA: Not Assigned。Awaiting Editorial Production Assistant Processing 刚提交显示这个正常吗？作者都没有收到邮件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=059b5442634, createdName=NWH, createdTime=Tue Feb 06 17:02:40 CST 2024, time=2024-02-06, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2119814, encodeId=4c2a211981487, content=偏重的研究方向：乳腺癌 经验分享：已经在Reviewer selection 和Reviewer Assignment之间反复横跳1个月了，煎熬。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Wed Mar 15 22:55:25 CST 2023, time=2023-03-15, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1223473, encodeId=4d9112234e326, content=审稿速度:1.0 经验分享：5月1 投稿 5月17 awaiting reviewer scores 5月26 告知主编将发decision letter 5月27 早上7:30，小修香港疫情好转，现在加班加点改稿子中，要补的一个实验猜中，提前在等待中做完了，希望好运🍀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=794e8145109, createdName=ms2000001308610491, createdTime=Mon May 30 23:16:38 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119822, encodeId=05ea211982212, content=这个杂志综述好投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ec38179859, createdName=ms5000001365142656, createdTime=Wed Mar 15 23:32:00 CST 2023, time=2023-03-15, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1057918, encodeId=6cda105e9181e, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗;病原生物 经验分享：再被cns子刊一顿拒稿之后，终于在这接收了。从投稿到接收，一直都非常迅速，感人主编很给力。 4.22提交 5.4一审大修遇到两个发nature大佬，提了一大堆意见，其中1号一直很很肯定我们的研究 6.23修回 7.14二审大修 2号审稿人同意接收，可惜1号换人了，提了几个和文章无关很无理的问题 9.15修回 9.24三审小修几个单词错误，迅速修回去 9.27修回 10.1 接收 希望大家都好运，搞个科研不容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/07/ccdcbbe305c3370f7fc7637823aaeac0.jpg, createdBy=07fb2397125, createdName=浅沫, createdTime=Tue Oct 05 16:42:40 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065742, encodeId=9dda1065e429f, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2600.0 偏重的研究方向：肿瘤免疫 经验分享：投稿两周，转态由 Awaiting reviewer selection 到Awaiting reviewer assignment 一周，10天左右变成Awaiting Recommendation，这是送外审还是没送哇，，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0985683001, createdName=ms3000001376117297, createdTime=Mon Nov 01 11:12:57 CST 2021, time=2021-11-01, status=1, ipAttribution=)]

2023-03-15 ms5000001365142656 来自天津

这个杂志综述好投吗？

47 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2180016, encodeId=3f3221800163f, content=Research Reporting Guideline checklist在哪里啊，没有找的呢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a6a8156000, createdName=ms1000000367938648, createdTime=Mon Jan 08 16:31:56 CST 2024, time=2024-01-08, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2142895, encodeId=efe42142895b8, content=为什么一直保持10分以上，还是中科院二区，还不如BMC medicine吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18525506506, createdName=ms4000001058776765, createdTime=Thu Jun 15 09:34:20 CST 2023, time=2023-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=911223, encodeId=111b91122357, content=现在状态是awaiting decision，是凉的意思吗？还是说内审决定送不送外审都会有这个状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48aa5286894, createdName=148555c3m25(暂无昵称), createdTime=Sun Dec 27 11:54:15 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997775, encodeId=d6f099e775b4, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤免疫;纳米 经验分享：03.17 投稿，很快进入审稿阶段； 04.06 大修，期限2个月； 05.05 大修返回，很快进入审稿阶段； 06.02 接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e91c38967, createdName=yelinghao215, createdTime=Fri Jul 09 08:38:11 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186239, encodeId=f23a218623976, content=EPA: Not Assigned。Awaiting Editorial Production Assistant Processing 刚提交显示这个正常吗？作者都没有收到邮件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=059b5442634, createdName=NWH, createdTime=Tue Feb 06 17:02:40 CST 2024, time=2024-02-06, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2119814, encodeId=4c2a211981487, content=偏重的研究方向：乳腺癌 经验分享：已经在Reviewer selection 和Reviewer Assignment之间反复横跳1个月了，煎熬。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Wed Mar 15 22:55:25 CST 2023, time=2023-03-15, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1223473, encodeId=4d9112234e326, content=审稿速度:1.0 经验分享：5月1 投稿 5月17 awaiting reviewer scores 5月26 告知主编将发decision letter 5月27 早上7:30，小修香港疫情好转，现在加班加点改稿子中，要补的一个实验猜中，提前在等待中做完了，希望好运🍀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=794e8145109, createdName=ms2000001308610491, createdTime=Mon May 30 23:16:38 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119822, encodeId=05ea211982212, content=这个杂志综述好投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ec38179859, createdName=ms5000001365142656, createdTime=Wed Mar 15 23:32:00 CST 2023, time=2023-03-15, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1057918, encodeId=6cda105e9181e, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗;病原生物 经验分享：再被cns子刊一顿拒稿之后，终于在这接收了。从投稿到接收，一直都非常迅速，感人主编很给力。 4.22提交 5.4一审大修遇到两个发nature大佬，提了一大堆意见，其中1号一直很很肯定我们的研究 6.23修回 7.14二审大修 2号审稿人同意接收，可惜1号换人了，提了几个和文章无关很无理的问题 9.15修回 9.24三审小修几个单词错误，迅速修回去 9.27修回 10.1 接收 希望大家都好运，搞个科研不容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/07/ccdcbbe305c3370f7fc7637823aaeac0.jpg, createdBy=07fb2397125, createdName=浅沫, createdTime=Tue Oct 05 16:42:40 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065742, encodeId=9dda1065e429f, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2600.0 偏重的研究方向：肿瘤免疫 经验分享：投稿两周，转态由 Awaiting reviewer selection 到Awaiting reviewer assignment 一周，10天左右变成Awaiting Recommendation，这是送外审还是没送哇，，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0985683001, createdName=ms3000001376117297, createdTime=Mon Nov 01 11:12:57 CST 2021, time=2021-11-01, status=1, ipAttribution=)]

2021-10-05 浅沫

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤免疫治疗;病原生物
经验分享：再被cns子刊一顿拒稿之后，终于在这接收了。从投稿到接收，一直都非常迅速，感人主编很给力。
4.22提交 5.4一审大修遇到两个发nature大佬，提了一大堆意见，其中1号一直很很肯定我们的研究
6.23修回 7.14二审大修 2号审稿人同意接收，可惜1号换人了，提了几个和文章无关很无理的问题
9.15修回 9.24三审小修几个单词错误，迅速修回去
9.27修回 10.1 接收
希望大家都好运，搞个科研不容易

123 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2180016, encodeId=3f3221800163f, content=Research Reporting Guideline checklist在哪里啊，没有找的呢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a6a8156000, createdName=ms1000000367938648, createdTime=Mon Jan 08 16:31:56 CST 2024, time=2024-01-08, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2142895, encodeId=efe42142895b8, content=为什么一直保持10分以上，还是中科院二区，还不如BMC medicine吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18525506506, createdName=ms4000001058776765, createdTime=Thu Jun 15 09:34:20 CST 2023, time=2023-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=911223, encodeId=111b91122357, content=现在状态是awaiting decision，是凉的意思吗？还是说内审决定送不送外审都会有这个状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48aa5286894, createdName=148555c3m25(暂无昵称), createdTime=Sun Dec 27 11:54:15 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997775, encodeId=d6f099e775b4, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤免疫;纳米 经验分享：03.17 投稿，很快进入审稿阶段； 04.06 大修，期限2个月； 05.05 大修返回，很快进入审稿阶段； 06.02 接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e91c38967, createdName=yelinghao215, createdTime=Fri Jul 09 08:38:11 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186239, encodeId=f23a218623976, content=EPA: Not Assigned。Awaiting Editorial Production Assistant Processing 刚提交显示这个正常吗？作者都没有收到邮件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=059b5442634, createdName=NWH, createdTime=Tue Feb 06 17:02:40 CST 2024, time=2024-02-06, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2119814, encodeId=4c2a211981487, content=偏重的研究方向：乳腺癌 经验分享：已经在Reviewer selection 和Reviewer Assignment之间反复横跳1个月了，煎熬。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Wed Mar 15 22:55:25 CST 2023, time=2023-03-15, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1223473, encodeId=4d9112234e326, content=审稿速度:1.0 经验分享：5月1 投稿 5月17 awaiting reviewer scores 5月26 告知主编将发decision letter 5月27 早上7:30，小修香港疫情好转，现在加班加点改稿子中，要补的一个实验猜中，提前在等待中做完了，希望好运🍀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=794e8145109, createdName=ms2000001308610491, createdTime=Mon May 30 23:16:38 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119822, encodeId=05ea211982212, content=这个杂志综述好投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ec38179859, createdName=ms5000001365142656, createdTime=Wed Mar 15 23:32:00 CST 2023, time=2023-03-15, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1057918, encodeId=6cda105e9181e, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗;病原生物 经验分享：再被cns子刊一顿拒稿之后，终于在这接收了。从投稿到接收，一直都非常迅速，感人主编很给力。 4.22提交 5.4一审大修遇到两个发nature大佬，提了一大堆意见，其中1号一直很很肯定我们的研究 6.23修回 7.14二审大修 2号审稿人同意接收，可惜1号换人了，提了几个和文章无关很无理的问题 9.15修回 9.24三审小修几个单词错误，迅速修回去 9.27修回 10.1 接收 希望大家都好运，搞个科研不容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/07/ccdcbbe305c3370f7fc7637823aaeac0.jpg, createdBy=07fb2397125, createdName=浅沫, createdTime=Tue Oct 05 16:42:40 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065742, encodeId=9dda1065e429f, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2600.0 偏重的研究方向：肿瘤免疫 经验分享：投稿两周，转态由 Awaiting reviewer selection 到Awaiting reviewer assignment 一周，10天左右变成Awaiting Recommendation，这是送外审还是没送哇，，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0985683001, createdName=ms3000001376117297, createdTime=Mon Nov 01 11:12:57 CST 2021, time=2021-11-01, status=1, ipAttribution=)]

2021-11-01 ms3000001376117297

审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2600.0
偏重的研究方向：肿瘤免疫
经验分享：投稿两周，转态由 Awaiting reviewer selection 到Awaiting reviewer assignment 一周，10天左右变成Awaiting Recommendation，这是送外审还是没送哇，，，，

94 5

展开5条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务